Biotech News
Related news
LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
VANIVivani Medical2026-05-28 12:30 EST
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
CVRXCVRx2026-05-27 20:30 EST
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
MLYSMineralys Therapeutics2026-05-27 12:00 EST
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
NAMSNewAmsterdam Pharma2026-04-08 12:00 EST
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
MISTMilestone Pharmaceuticals Inc.2026-04-07 12:30 EST
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
MLYSMineralys Therapeutics2026-06-08 20:05 EST
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BLTEBelite Bio2026-06-02 12:00 EST
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
CVRXCVRx2026-07-28 12:30 EST
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
VANIVivani Medical2026-07-14 20:03 EST
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-07-29 10:30 EST
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MNKDMannKind2026-07-24 10:35 EST
MannKind Announces $50 Million Private Placement
MNKDMannKind2026-07-24 10:30 EST
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
Stock data
- Close
- 3.89 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States